Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E.

Vaccine. 2008 Aug 12;26(34):4382-6. doi: 10.1016/j.vaccine.2008.05.081. Epub 2008 Jun 17.

PMID:
18599165
3.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

5.

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A.

J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. Erratum in: J Infect Dis. 2010 Apr 15;201(8):1278.

6.

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

Schuller E, Klade CS, Heinz FX, Kollaritsch H, Rendi-Wagner P, Jilma B, Tauber E.

Vaccine. 2008 Nov 11;26(48):6151-6. doi: 10.1016/j.vaccine.2008.08.056. Epub 2008 Sep 17.

PMID:
18804132
7.

Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.

Reisler RB, Danner DK, Gibbs PH.

Vaccine. 2010 Mar 11;28(12):2436-41. doi: 10.1016/j.vaccine.2009.12.080. Epub 2010 Jan 8.

PMID:
20060946
8.

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, Towle AC, Vaughn DW, Innis BL, Eckels KH.

Vaccine. 2001 Aug 14;19(31):4557-65.

PMID:
11483284
9.

Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.

Woolpert T, Staples JE, Faix DJ, Nett RJ, Kosoy OI, Biggerstaff BJ, Johnson BW, Sracic M, Fischer M.

Vaccine. 2012 Apr 26;30(20):3090-6. doi: 10.1016/j.vaccine.2012.02.063. Epub 2012 Mar 6.

PMID:
22406277
10.

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine.

Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, Nishiyama K, Sugawara K, Takeda K, Honda T, Matsui H, Shigaki T, Kino Y, Mizokami H, Tanaka M, Mizuno K, Ueda K.

Vaccine. 2003 Nov 7;21(31):4519-26.

PMID:
14575762
11.

Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.

Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E.

Vaccine. 2010 Sep 7;28(39):6463-9. doi: 10.1016/j.vaccine.2010.07.040. Epub 2010 Jul 29.

PMID:
20673824
12.

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E.

Vaccine. 2009 Jul 16;27(33):4483-9. doi: 10.1016/j.vaccine.2009.05.034. Epub 2009 May 30.

PMID:
19486955
14.
15.

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.

Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E.

Vaccine. 2009 Mar 26;27(15):2188-93. doi: 10.1016/j.vaccine.2008.12.062. Epub 2009 Feb 4.

PMID:
19200452
16.
17.

Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 Mar 12;59(RR-1):1-27.

18.

Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).

Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Namazue J, Fuke I, Ishikawa T, Okuno Y, Ueda S.

Vaccine. 2012 Mar 16;30(13):2329-35. doi: 10.1016/j.vaccine.2012.01.054. Epub 2012 Jan 31.

PMID:
22306856
19.

Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).

Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z.

Vaccine. 2011 Nov 3;29(47):8669-76. doi: 10.1016/j.vaccine.2011.08.117. Epub 2011 Sep 10.

PMID:
21907747
20.

Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.

Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T.

Vaccine. 2015 Jul 9;33(30):3600-4. doi: 10.1016/j.vaccine.2015.05.037. Epub 2015 May 30.

PMID:
26036947
Items per page

Supplemental Content

Write to the Help Desk